Associated Papers
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants.
Liu N et al.
Translational Neurodegeneration, 2025
The hexosamine biosynthetic pathway rescues lysosomal dysfunction in Parkinson's disease patient iPSC derived midbrain neurons.
Wani WY et al.
Nature Communications, 2024
Parkinson's disease-associated mutations in α-synuclein alters its lipid-bound state.
Maltseva S et al.
Biophysical Journal, 2024
Neuronal identity defines α-synuclein and tau toxicity.
Praschberger R et al.
Neuron, 2023
Interaction Between the Glymphatic System and α-Synuclein in Parkinson's Disease.
Zhang Y et al.
Molecular Neurobiology, 2023
Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models.
Chin RM et al.
Biorxiv : the Preprint Server for Biology, 2023
Succinate dehydrogenase variants in paraganglioma: why are B subunit variants 'bad'?
Gruber LM et al.
Endocrine Oncology (bristol, England), 2023
Anionic lipid vesicles have differential effects on the aggregation of early onset-associated α-synuclein missense mutants.
Watt KJC et al.
The Journal of Biological Chemistry, 2022
The E46K mutation modulates α-synuclein prion replication in transgenic mice.
Holec SAM et al.
Plos Pathogens, 2022
DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers.
Jin M et al.
Nature Communications, 2022
Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts.
Petropoulou-Vathi L et al.
Npj Parkinson's Disease, 2022
Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of α-synuclein.
Ohgita T et al.
Scientific Reports, 2022
Cytosolic aggregation of mitochondrial proteins disrupts cellular homeostasis by stimulating the aggregation of other proteins.
Nowicka U et al.
Elife, 2021
Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction.
Yu Z et al.
Brain : a Journal of Neurology, 2020
Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by α-Synuclein.
Cuddy LK et al.
Neuron, 2019
Replication of multiple system atrophy prions in primary astrocyte cultures from transgenic mice expressing human α-synuclein.
Krejciova Z et al.
Acta Neuropathologica Communications, 2019
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA et al.
Acs Chemical Neuroscience, 2019
A sensitive assay reveals structural requirements for α-synuclein fibril growth.
Dhavale DD et al.
The Journal of Biological Chemistry, 2017
Extracellular α-synuclein induces sphingosine 1-phosphate receptor subtype 1 uncoupled from inhibitory G-protein leaving β-arrestin signal intact.
Zhang L et al.
Scientific Reports, 2017
The chaperonin CCT inhibits assembly of α-synuclein amyloid fibrils by a specific, conformation-dependent interaction.
Sot B et al.
Scientific Reports, 2017
Transient β-hairpin formation in α-synuclein monomer revealed by coarse-grained molecular dynamics simulation.
Yu H et al.
The Journal of Chemical Physics, 2015
Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of α-synuclein.
Sahay S et al.
The Journal of Biological Chemistry, 2015
Germline FH mutations presenting with pheochromocytoma.
Clark GR et al.
The Journal of Clinical Endocrinology and Metabolism, 2014
Familial Parkinson disease mutations influence α-synuclein assembly.
Ono K et al.
Neurobiology of Disease, 2011
Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease.
Lee YJ et al.
Plos One, 2011
Novel suppressors of alpha-synuclein toxicity identified using yeast.
Liang J et al.
Human Molecular Genetics, 2008
Tissue transglutaminase modulates alpha-synuclein oligomerization.
Segers-Nolten IM et al.
Protein Science : a Publication of the Protein Society, 2008
Sequence determinants regulating fibrillation of human alpha-synuclein.
Koo HJ et al.
Biochemical and Biophysical Research Communications, 2008
alpha-Synucleinopathy models and human neuropathology: similarities and differences.
Kahle PJ
Acta Neuropathologica, 2008
YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation.
Flower TR et al.
The Journal of Cell Biology, 2007
Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells.
Tehranian R et al.
Journal of Neurochemistry, 2006
Alpha-synuclein overexpression increases cytosolic catecholamine concentration.
Mosharov EV et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2006
Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast.
Dixon C et al.
Genetics, 2005
Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
Li W et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2004
alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis.
Jo E et al.
European Journal of Biochemistry, 2004
Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
Bussell R et al.
Biochemistry, 2004